What the FDA labels say about taking them together
Capecitabine and ixabepilone
Ixabepilone's FDA label of December 4, 2025 names capecitabine in its boxed warning section; the capecitabine label PlainMeds reads does not name ixabepilone. The ixabepilone label: “IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN.”
Check it at the source: the capecitabine FDA label on DailyMed (effective February 5, 2026, H2-Pharma, LLC); the ixabepilone FDA label on DailyMed (effective December 4, 2025, R-Pharm US Operating, LLC).
What does the capecitabine label say about ixabepilone?
Capecitabine's label (effective February 5, 2026) does not name ixabepilone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (XELODA), NDA020896 (Cheplapharm), as published by H2-Pharma, LLC, effective February 5, 2026 (SPL set e702d84d-7162-4751-bf37-d724cc7e45a5), via openFDA; the full label on DailyMed
What does the ixabepilone label say about capecitabine?
Ixabepilone label, boxed warningTOXICITY IN PATIENTS WITH HEPATIC IMPAIRMENT IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )].
Ixabepilone label, contraindicationsIXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN [see Boxed Warning and Warnings and Precautions ( 5.3 )].
Ixabepilone label, drug interactionsIn patients with cancer who received ixabepilone (40 mg/m 2 ) in combination with capecitabine (1000 mg/m 2 ), ixabepilone Cmax decreased by 19%, capecitabine Cmax decreased by 27%, and 5-fluorouracil AUC increased by 14%, as compared to ixabepilone or capecitabine administered separately.
Ixabepilone label, warnings and precautionswith capecitabine; Single Agent
Source: FDA drug label (IXEMPRA), R-Pharm US Operating, LLC, effective December 4, 2025 (SPL set 241f0b1e-8b95-470d-876f-bf1804daaf18), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Capecitabine | Ixabepilone | |
|---|---|---|
| Labeled for | Colorectal cancer, Breast cancer | Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.456 per tablet 500 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once